Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Ben Wa who wrote (4514)	6/12/2003 6:43:30 PM
From: StockDung	Read Replies (2) \| Respond to of 5582

TOP SECRET SLEEP SPRAY TO REACH MARKET! =================================================== Med Gen to Start Marketing New Liquid Sleep Aid Monday June 9, 11:23 am ET BOCA RATON, Fla.--(BUSINESS WIRE)--June 9, 2003--Med Gen Inc. (OTCBB:MDGN - News), makers of the now well known brand Snorenz®, all natural liquid snoring relief formula now sold in over 35,000 stores world wide, will introduce its new, first ever, liquid sleep aid product to its retail accounts starting July 10th, 2003. GoodNights Sleep(TM) has been under development by the company for over one year and kept under a blanket of top secrecy as it will be the first liquid spray of its kind, competing with a plethora of pill and capsule sleep aide products. The liquid spray application, using its special manufacturing process, is designed to enter the body faster and easier through absorption by the mucous membrane in the throat thus delivering its dosage directly into the blood stream without going into the stomach and the liver where pills and capsules lose a lot of their potency. The market for over the counter sleep aid products exceeds $350 million in the United States alone, the worldwide market place is said to exceed $1.7 Billion. The company intends to market GoodNights Sleep(TM) through its regular channels of distribution and the product has already been accepted in three major chains for early distribution. Because of its success with Snorenz®, the company expects that it will quickly reach the shelves of the 35,000 stores now distributing Snorenz®. Med Gen President Paul S. Mitchell said he expects to reach 1% of the existing market ($350 Million) by the first year. Thus adding $3.5 million in sales or doubling 2002 sales figures is a good projection for the first 12 months sales. Mr. Mitchell added that the sales are wide open for this kind of product that is now dominated by Sominex®, ExcedrinPM® and other "pill" products and he reports that the company has already received its first purchase order from Albertson's for immediate delivery. The market for sleep aid products is a fast growing market. This Press Release contains or incorporates by reference "forward looking" statements including certain information with respect to plans and strategies of Med Gen Inc. ("MedGen®"). For this purpose, any statements contained herein or incorporated herein by references that are not statements of historical fact may be deemed forward looking statements. Without limiting the foregoing, the words "believes", "suggests", "anticipates", "plans", "expects", and similar expressions are intended to identify forward looking statements. There are a number of events or actual results of MedGen® operations that could differ materially from those indicated by such forward looking statements. MedGen® is a publicly traded company on the OTCBB exchange "MDGN". -------------------------------------------------------------------------------- Contact: Med Gen Inc., Boca Raton Paul Kravitz, 561/750-1100 medgen.com forgoodnightssleep.com thehealthytimes.com ============================================ AND LAST BUT NOT LEAST, EXCUSE ME.... I MEANT TO SAY FINALLY thehealthytimes.com -------------------------------------------- ALSO SEE; -------------------------------------------------------------------------------- 1: Tru-Vantage International, LLC/Med Gen, Inc. truvanmedgen.htm, Search in: News_Releases File size: 13K, Create Date: Aug-27-02 14:29 ftc.gov 2: Announced Actions for July 19, 2002 fyi0240.htm, Search in: News_Releases File size: 12K, Create Date: Apr-01-03 16:52 ftc.gov 3: Eye Doctor That Purportedly Conducted Tests to Support The Efficacy of a Product to Treat Snoring Settles FTC Charges currier.htm, Search in: News_Releases File size: 12K, Create Date: Nov-06-02 09:45 ftc.gov 4: News Releases: July 2002 index.htm, Search in: News_Releases File size: 17K, Create Date: Aug-12-02 07:35 ftc.gov

To: Ben Wa who wrote (4514)	6/12/2003 9:12:07 PM
From: StockDung	Respond to of 5582

The Quigley Corporation Introduces KIDZ-EEZE Lollipop to Soothe Sore Throats Thursday April 10, 7:30 am ET First Product in Quigley Line Targeted Specifically To Kids DOYLESTOWN, Pa.--(BUSINESS WIRE)--April 10, 2003--The Quigley Corporation (Nasdaq:QGLY - News), marketer and distributor of COLD-EEZE®, the nation's leading pharmacist recommended over-the-counter zinc cold remedy, announced today the introduction of a sore throat lollipop under its all-new KIDZ-EEZE(TM) banner. Featuring pectin to soothe sore throats, the KIDZ-EEZE Sore Throat Pop will begin shipping to retail in August 2003. This introduction marks the first time that The Quigley Corporation has developed a product specifically addressing children's sore throats. The KIDZ-EEZE Sore Throat Pop, containing 20 mg of pectin, is designed to soothe sore throats, one of the primary symptoms of the common cold. The pops, which also include 30 mg of Vitamin C and 4.4 mg of Zinc Gluconate, will be available in a random assortment of four great-tasting flavors: cherry, grape, orange and bubblegum. "Combined with the recent announcement of our COLD-EEZE Zinc Gluconate Cold Remedy Nasal Spray, the debut of the KIDZ-EEZE Sore Throat Pop solidifies our position as a leader in the cold care category," said Guy J. Quigley, Chairman, President and Chief Executive Officer of The Quigley Corporation. "We are confident that this newest offering will appeal to parents and kids, while satisfying our retail customers with new, related Quigley products." Packaging for the KIDZ-EEZE Sore Throat Pops will leverage the popularity of the COLD-EEZE brand while also clearly displaying the new KIDZ-EEZE logo. The launch of the pops will be supported with an integrated marketing campaign, including advertising, public relations and in-store support. About The Quigley Corporation The Quigley Corporation (Nasdaq:QGLY - News; www.quigleyco.com) is a leading developer and marketer of diversified health products including the COLD-EEZE® family of patented zinc gluconate glycine (ZIGG(TM)) lozenges, gums and sugar free tablets. COLD-EEZE is the only (ZIGG(TM)) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. Additional information about The Quigley Corporation is available on its Web site at www.quigleyco.com. Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations and worldwide competition. -------------------------------------------------------------------------------- Contact: G.S. Schwartz & Co., New York Alissa Pinck (media), 212/725-4500 apinck@schwartz.com or The Investor Relations Group, New York Lisa Lindberg (investors), 212/825-3210 theproteam@aol.com -------------------------------------------------------------------------------- Source: The Quigley Corp.